KEYNOTE-F89, NCT06234397: Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 245 | US, RoW | BH3120, pembrolizumab, KEYTRUDA® | Hanmi Pharmaceutical Company Limited, Merck Sharp & Dohme LLC | Advanced or Metastatic Solid Tumors | 08/27 | 01/28 | | |
